Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Asset Writedowns and Impairment (2022 - 2024)

Historic Asset Writedowns and Impairment for OptimizeRx (OPRX) over the last 3 years, with Q4 2024 value amounting to $7.4 million.

  • OptimizeRx's Asset Writedowns and Impairment rose 1753.99% to $7.4 million in Q4 2024 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 1513.07%. This contributed to the annual value of $7.5 million for FY2024, which is 1114.57% up from last year.
  • Per OptimizeRx's latest filing, its Asset Writedowns and Impairment stood at $7.4 million for Q4 2024, which was up 1753.99% from -$1000.0 recorded in Q3 2024.
  • OptimizeRx's Asset Writedowns and Impairment's 5-year high stood at $7.4 million during Q4 2024, with a 5-year trough of -$1000.0 in Q3 2024.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $128000.0 (2023), whereas its average is $1.3 million.
  • In the last 5 years, OptimizeRx's Asset Writedowns and Impairment soared by 261248.13% in 2023 and then crashed by 10041.84% in 2024.
  • Quarter analysis of 3 years shows OptimizeRx's Asset Writedowns and Impairment stood at $230785.0 in 2022, then surged by 2612.48% to $6.3 million in 2023, then rose by 17.54% to $7.4 million in 2024.
  • Its Asset Writedowns and Impairment was $7.4 million in Q4 2024, compared to -$1000.0 in Q3 2024 and $132000.0 in Q1 2024.